Telehealth sees rising off-label use of GLP-1s for substance abuse
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
GLP-1 injections recalled nationwide in the US over concerning reason
A popular weight-loss shot has been recalled across the US by the Food and Drug Administration due to…
Why this startup is taking its AI to predict breast-cancer risk directly to patients
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
What ‘Asian glow’ means for patients’ long-term health and drinking
I was 8 years old, sitting at dinner with my grandparents, watching Gong Gong’s face turn bright red…
Doctors Share The Habits They Changed After Seeing Patients Suffer
People who work in medical professions, like doctors, nurses, and EMTs, often see firsthand what can happen to…
The new GLP-1 weight-loss pill vs. the shot: a doctor’s answer on oral Wegovy
FDA approved the Wegovy pill, the first oral semaglutide for weight management, in late December 2025, and it…
Reddit menopause forums may be capturing what doctors miss
In forums on Reddit, women share tales of having perimenopause and menopause symptoms misdiagnosed or dismissed as mental…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS…
I’m A Doctor. This Harmful Reality Of American Health Care Is Becoming Normalized.
A week before her dental surgery, one of my patients came to me with a question. She had…
EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…
The new GLP-1 weight-loss pill vs. the shot: A doctor’s honest answer on oral Wegovy
FDA approved the Wegovy pill, the first oral semaglutide for weight management, in late December 2025, and it…